TLSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TriSalus Life Sciences Inc (TLSI) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has potential upside based on the analyst's raised price target and bullish sector outlook, the lack of significant trading trends, weak financial performance in the latest quarter, and absence of recent positive news or catalysts suggest that it is better to wait for more favorable conditions or stronger signals before investing.
The MACD is positive and expanding, indicating a potential upward momentum. RSI is neutral at 62.91, and moving averages are converging, showing no strong directional trend. The stock is trading near its resistance level (R1: 5.447), which could act as a barrier to further immediate price increases.
Analyst raised the price target to $12 from $11 with a Buy rating, citing bullish sentiment on the Med-Tech sector due to strong demand, M&A activity, and a receptive market for IPOs.
No significant trading trends from hedge funds or insiders. No recent news or congress trading data to indicate positive sentiment.
In Q4 2025, revenue increased by 59.79% YoY to $13.2 million. However, net income, EPS, and gross margin all dropped to 0, reflecting poor profitability and operational efficiency.
Canaccord analyst William Plovanic raised the price target to $12 from $11 and maintained a Buy rating, citing a positive outlook for the Med-Tech sector heading into 2026.
